Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue.
Identifieur interne : 000F53 ( PubMed/Checkpoint ); précédent : 000F52; suivant : 000F54Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue.
Auteurs : Valérie Cochen [France] ; Maria-Joao Ribeiro ; Jean-Paul Nguyen ; Jean-Marc Gurruchaga ; Gabriel Villafane ; Christian Loc'H ; Gilles Defer ; Yves Samson ; Marc Peschanski ; Philippe Hantraye ; Pierre Cesaro ; Philippe RemySource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2003.
English descriptors
- KwdEn :
- Aged, Corpus Striatum (metabolism), Dopamine Plasma Membrane Transport Proteins, Female, Fetal Tissue Transplantation (methods), Fluorodeoxyglucose F18 (pharmacokinetics), Graft Rejection (prevention & control), Humans, Immunosuppressive Agents (therapeutic use), Male, Membrane Glycoproteins, Membrane Transport Proteins (metabolism), Mesencephalon (embryology), Mesencephalon (metabolism), Mesencephalon (transplantation), Middle Aged, Nerve Tissue Proteins, Parkinson Disease (diagnosis), Parkinson Disease (surgery), Radiopharmaceuticals (pharmacokinetics), Tomography, Emission-Computed.
- MESH :
- chemical , metabolism : Membrane Transport Proteins.
- chemical , pharmacokinetics : Fluorodeoxyglucose F18, Radiopharmaceuticals.
- chemical , therapeutic use : Immunosuppressive Agents.
- chemical : Dopamine Plasma Membrane Transport Proteins, Membrane Glycoproteins, Nerve Tissue Proteins.
- diagnosis : Parkinson Disease.
- embryology : Mesencephalon.
- metabolism : Corpus Striatum, Mesencephalon.
- methods : Fetal Tissue Transplantation.
- prevention & control : Graft Rejection.
- surgery : Parkinson Disease.
- transplantation : Mesencephalon.
- Aged, Female, Humans, Male, Middle Aged, Tomography, Emission-Computed.
Abstract
We compared the striatal uptake of [(18)F]fluorodopa with [(76)Br]-FE-CBT, a positron emission tomography (PET) ligand of the dopamine transporter (DAT), which estimates the density of dopamine nerve terminals, in 6 patients with Parkinson's disease grafted with fetal mesencephalic cells. There was no change in DAT ligand binding in the grafted putamen, despite a significant increase of [(18)F]fluorodopa uptake. This finding suggests that the clinical benefit induced by the graft is more related to increased dopaminergic activity than improved dopaminergic innervation in the host striatum and, therefore, that [(18)F]fluorodopa remains the optimal tracer to evaluate grafted PD patients. Further analysis showed that the clinical and [(18)F]fluorodopa uptake changes after the grafts were correlated with the number of ventral mesencephalae used for implantation.
DOI: 10.1002/mds.10463
PubMed: 12889084
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:12889084Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue.</title><author><name sortKey="Cochen, Valerie" sort="Cochen, Valerie" uniqKey="Cochen V" first="Valérie" last="Cochen">Valérie Cochen</name><affiliation wicri:level="3"><nlm:affiliation>Unité de Recherche Associée Commissariat à l'Energie Atomique (CEA)-Centre National de la Recherche Scientifique (CNRS) 2210, Orsay, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité de Recherche Associée Commissariat à l'Energie Atomique (CEA)-Centre National de la Recherche Scientifique (CNRS) 2210, Orsay</wicri:regionArea><placeName><settlement type="city">Orsay</settlement></placeName></affiliation></author><author><name sortKey="Ribeiro, Maria Joao" sort="Ribeiro, Maria Joao" uniqKey="Ribeiro M" first="Maria-Joao" last="Ribeiro">Maria-Joao Ribeiro</name></author><author><name sortKey="Nguyen, Jean Paul" sort="Nguyen, Jean Paul" uniqKey="Nguyen J" first="Jean-Paul" last="Nguyen">Jean-Paul Nguyen</name></author><author><name sortKey="Gurruchaga, Jean Marc" sort="Gurruchaga, Jean Marc" uniqKey="Gurruchaga J" first="Jean-Marc" last="Gurruchaga">Jean-Marc Gurruchaga</name></author><author><name sortKey="Villafane, Gabriel" sort="Villafane, Gabriel" uniqKey="Villafane G" first="Gabriel" last="Villafane">Gabriel Villafane</name></author><author><name sortKey="Loc H, Christian" sort="Loc H, Christian" uniqKey="Loc H C" first="Christian" last="Loc'H">Christian Loc'H</name></author><author><name sortKey="Defer, Gilles" sort="Defer, Gilles" uniqKey="Defer G" first="Gilles" last="Defer">Gilles Defer</name></author><author><name sortKey="Samson, Yves" sort="Samson, Yves" uniqKey="Samson Y" first="Yves" last="Samson">Yves Samson</name></author><author><name sortKey="Peschanski, Marc" sort="Peschanski, Marc" uniqKey="Peschanski M" first="Marc" last="Peschanski">Marc Peschanski</name></author><author><name sortKey="Hantraye, Philippe" sort="Hantraye, Philippe" uniqKey="Hantraye P" first="Philippe" last="Hantraye">Philippe Hantraye</name></author><author><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name></author><author><name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:12889084</idno><idno type="pmid">12889084</idno><idno type="doi">10.1002/mds.10463</idno><idno type="wicri:Area/PubMed/Corpus">001089</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001089</idno><idno type="wicri:Area/PubMed/Curation">001048</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001048</idno><idno type="wicri:Area/PubMed/Checkpoint">001048</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001048</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue.</title><author><name sortKey="Cochen, Valerie" sort="Cochen, Valerie" uniqKey="Cochen V" first="Valérie" last="Cochen">Valérie Cochen</name><affiliation wicri:level="3"><nlm:affiliation>Unité de Recherche Associée Commissariat à l'Energie Atomique (CEA)-Centre National de la Recherche Scientifique (CNRS) 2210, Orsay, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Unité de Recherche Associée Commissariat à l'Energie Atomique (CEA)-Centre National de la Recherche Scientifique (CNRS) 2210, Orsay</wicri:regionArea><placeName><settlement type="city">Orsay</settlement></placeName></affiliation></author><author><name sortKey="Ribeiro, Maria Joao" sort="Ribeiro, Maria Joao" uniqKey="Ribeiro M" first="Maria-Joao" last="Ribeiro">Maria-Joao Ribeiro</name></author><author><name sortKey="Nguyen, Jean Paul" sort="Nguyen, Jean Paul" uniqKey="Nguyen J" first="Jean-Paul" last="Nguyen">Jean-Paul Nguyen</name></author><author><name sortKey="Gurruchaga, Jean Marc" sort="Gurruchaga, Jean Marc" uniqKey="Gurruchaga J" first="Jean-Marc" last="Gurruchaga">Jean-Marc Gurruchaga</name></author><author><name sortKey="Villafane, Gabriel" sort="Villafane, Gabriel" uniqKey="Villafane G" first="Gabriel" last="Villafane">Gabriel Villafane</name></author><author><name sortKey="Loc H, Christian" sort="Loc H, Christian" uniqKey="Loc H C" first="Christian" last="Loc'H">Christian Loc'H</name></author><author><name sortKey="Defer, Gilles" sort="Defer, Gilles" uniqKey="Defer G" first="Gilles" last="Defer">Gilles Defer</name></author><author><name sortKey="Samson, Yves" sort="Samson, Yves" uniqKey="Samson Y" first="Yves" last="Samson">Yves Samson</name></author><author><name sortKey="Peschanski, Marc" sort="Peschanski, Marc" uniqKey="Peschanski M" first="Marc" last="Peschanski">Marc Peschanski</name></author><author><name sortKey="Hantraye, Philippe" sort="Hantraye, Philippe" uniqKey="Hantraye P" first="Philippe" last="Hantraye">Philippe Hantraye</name></author><author><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name></author><author><name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Corpus Striatum (metabolism)</term><term>Dopamine Plasma Membrane Transport Proteins</term><term>Female</term><term>Fetal Tissue Transplantation (methods)</term><term>Fluorodeoxyglucose F18 (pharmacokinetics)</term><term>Graft Rejection (prevention & control)</term><term>Humans</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Male</term><term>Membrane Glycoproteins</term><term>Membrane Transport Proteins (metabolism)</term><term>Mesencephalon (embryology)</term><term>Mesencephalon (metabolism)</term><term>Mesencephalon (transplantation)</term><term>Middle Aged</term><term>Nerve Tissue Proteins</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (surgery)</term><term>Radiopharmaceuticals (pharmacokinetics)</term><term>Tomography, Emission-Computed</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Membrane Transport Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Fluorodeoxyglucose F18</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Dopamine Plasma Membrane Transport Proteins</term><term>Membrane Glycoproteins</term><term>Nerve Tissue Proteins</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="embryology" xml:lang="en"><term>Mesencephalon</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Corpus Striatum</term><term>Mesencephalon</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Fetal Tissue Transplantation</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Graft Rejection</term></keywords><keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="transplantation" xml:lang="en"><term>Mesencephalon</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Tomography, Emission-Computed</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the striatal uptake of [(18)F]fluorodopa with [(76)Br]-FE-CBT, a positron emission tomography (PET) ligand of the dopamine transporter (DAT), which estimates the density of dopamine nerve terminals, in 6 patients with Parkinson's disease grafted with fetal mesencephalic cells. There was no change in DAT ligand binding in the grafted putamen, despite a significant increase of [(18)F]fluorodopa uptake. This finding suggests that the clinical benefit induced by the graft is more related to increased dopaminergic activity than improved dopaminergic innervation in the host striatum and, therefore, that [(18)F]fluorodopa remains the optimal tracer to evaluate grafted PD patients. Further analysis showed that the clinical and [(18)F]fluorodopa uptake changes after the grafts were correlated with the number of ventral mesencephalae used for implantation.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12889084</PMID><DateCreated><Year>2003</Year><Month>07</Month><Day>30</Day></DateCreated><DateCompleted><Year>2004</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>8</Issue><PubDate><Year>2003</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue.</ArticleTitle><Pagination><MedlinePgn>928-32</MedlinePgn></Pagination><Abstract><AbstractText>We compared the striatal uptake of [(18)F]fluorodopa with [(76)Br]-FE-CBT, a positron emission tomography (PET) ligand of the dopamine transporter (DAT), which estimates the density of dopamine nerve terminals, in 6 patients with Parkinson's disease grafted with fetal mesencephalic cells. There was no change in DAT ligand binding in the grafted putamen, despite a significant increase of [(18)F]fluorodopa uptake. This finding suggests that the clinical benefit induced by the graft is more related to increased dopaminergic activity than improved dopaminergic innervation in the host striatum and, therefore, that [(18)F]fluorodopa remains the optimal tracer to evaluate grafted PD patients. Further analysis showed that the clinical and [(18)F]fluorodopa uptake changes after the grafts were correlated with the number of ventral mesencephalae used for implantation.</AbstractText><CopyrightInformation>Copyright 2003 Movement Disorder Society</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cochen</LastName><ForeName>Valérie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Unité de Recherche Associée Commissariat à l'Energie Atomique (CEA)-Centre National de la Recherche Scientifique (CNRS) 2210, Orsay, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>Maria-Joao</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Jean-Paul</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Gurruchaga</LastName><ForeName>Jean-Marc</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Villafane</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Loc'h</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Defer</LastName><ForeName>Gilles</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Samson</LastName><ForeName>Yves</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Peschanski</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Hantraye</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Cesaro</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Remy</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050483">Dopamine Plasma Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D026901">Membrane Transport Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009419">Nerve Tissue Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C493214">SLC6A3 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Mov Disord. 2004 Jan;19(1):119</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050483" MajorTopicYN="N">Dopamine Plasma Membrane Transport Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016332" MajorTopicYN="N">Fetal Tissue Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="Y">Membrane Glycoproteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D026901" MajorTopicYN="N">Membrane Transport Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008636" MajorTopicYN="N">Mesencephalon</DescriptorName><QualifierName UI="Q000196" MajorTopicYN="N">embryology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000637" MajorTopicYN="Y">transplantation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009419" MajorTopicYN="Y">Nerve Tissue Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="Y">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>31</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12889084</ArticleId><ArticleId IdType="doi">10.1002/mds.10463</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><settlement><li>Orsay</li></settlement></list><tree><noCountry><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name><name sortKey="Defer, Gilles" sort="Defer, Gilles" uniqKey="Defer G" first="Gilles" last="Defer">Gilles Defer</name><name sortKey="Gurruchaga, Jean Marc" sort="Gurruchaga, Jean Marc" uniqKey="Gurruchaga J" first="Jean-Marc" last="Gurruchaga">Jean-Marc Gurruchaga</name><name sortKey="Hantraye, Philippe" sort="Hantraye, Philippe" uniqKey="Hantraye P" first="Philippe" last="Hantraye">Philippe Hantraye</name><name sortKey="Loc H, Christian" sort="Loc H, Christian" uniqKey="Loc H C" first="Christian" last="Loc'H">Christian Loc'H</name><name sortKey="Nguyen, Jean Paul" sort="Nguyen, Jean Paul" uniqKey="Nguyen J" first="Jean-Paul" last="Nguyen">Jean-Paul Nguyen</name><name sortKey="Peschanski, Marc" sort="Peschanski, Marc" uniqKey="Peschanski M" first="Marc" last="Peschanski">Marc Peschanski</name><name sortKey="Remy, Philippe" sort="Remy, Philippe" uniqKey="Remy P" first="Philippe" last="Remy">Philippe Remy</name><name sortKey="Ribeiro, Maria Joao" sort="Ribeiro, Maria Joao" uniqKey="Ribeiro M" first="Maria-Joao" last="Ribeiro">Maria-Joao Ribeiro</name><name sortKey="Samson, Yves" sort="Samson, Yves" uniqKey="Samson Y" first="Yves" last="Samson">Yves Samson</name><name sortKey="Villafane, Gabriel" sort="Villafane, Gabriel" uniqKey="Villafane G" first="Gabriel" last="Villafane">Gabriel Villafane</name></noCountry><country name="France"><noRegion><name sortKey="Cochen, Valerie" sort="Cochen, Valerie" uniqKey="Cochen V" first="Valérie" last="Cochen">Valérie Cochen</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000F53 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000F53 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:12889084
|texte= Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:12889084" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |